Ten years of infliximab: Insights from clinical trials in rheumatoid arthritis

European Journal of Pharmacology

Volumn 623, Issue SUPPL.1, 2009, Pages

  Smolen, Josef S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clinical trial; Infliximab; Rheumatoid arthritis; Tumor necrosis factor (TNF)

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; CLINICAL TRIAL; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY INTERVENTION; HUMAN; IMMUNOGENICITY; LUPUS VULGARIS; MONOTHERAPY; NEPHRITIS; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TUBERCULOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 71549158843     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.026     Document Type: Review

References (62)

1. Aletaha D., Smolen J., and Ward M.M. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum. 54 (2006) 2784-2792
2. Aringer M., Graninger W.B., Steiner G., and Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50 (2004) 3161-3169
3. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., Genovese M.C., Wasko M.C., Moreland L.W., Weaver A.L., Markenson J., and Finck B.K. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343 22 (2000) 1586-1593
4. Bobbio-Pallavicini F., Alpini C., Caporali R., Avalle S., Bugatti S., and Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res. Ther. 6 (2004) R264-R267
5. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., Sharp J., Perez J.L., and Spencer-Green G.T. The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54 (2006) 26-37
6. Brennan F.M., Chantry D., Jackson A., Maini R., and Feldmann M. Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2 (1989) 244-247
7. Brennan F.M., Maini R.N., and Feldmann M. TNF alpha-a pivotal role in rheumatoid arthritis?. Br. J. Rheumatol. 31 5 (1992) 293-298
8. Buchan G., Barrett K., Turner M., Chantry D., Maini R.N., and Feldmann M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin. Exp. Immunol. 73 3 (1988) 449-455
9. Burmester G.R., Mariette X., Montecucco C., Monteagudo-Saez I., Malaise M., Tzioufas A.G., Bijlsma J.W.J., Unnebrink K., Kary S., and Kupper H. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann. Rheum. Dis. 66 6 (2007) 732-739
10. Chu C.Q., Field M., Feldmann M., and Maini R.N. Localization of tumor-necrosis factor-alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34 (1991) 1125-1132
11. Dawes P.T., Fowler P.D., Clarke S., Fisher J., Lawton A., and Shadforth M.F. Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br. J. Rheumatol. 25 (1986) 44-49
12. Diener E., and Feldmann M. Antibody-mediated suppression of the immune response in vitro. II. A new approach to the phenomenon of immunological tolerance. J. Exp. Med. 132 1 (1970) 31-43
13. Diener E., and Feldmann M. Mechanisms at the cellular level during induction of high zone tolerance in vitro. Cell. Immunol. 5 1 (1972) 130-136
14. Drossaers-Bakker K.W., de Buck M., van Zeben D., Zwinderman A.H., Breedveld F.C., and Hazes J.M. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 42 (1999) 1854-1860
15. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F.M., Walker J., Bijl H., Ghrayeb J., and Woody J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36 12 (1993) 1681-1690
16. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni A., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H., and Woody J.N. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 8930 (1994) 1105-1110
17. Emery P., Breedveld F.C., Hall S., Durez P., Chang D.J., Robertson D., Singh A., Pedersen R.D., Koenig A.S., and Freundlich B. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372 9636 (2008) 375-382
18. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14 (1996) 397-440
19. Firestein G.S., Alvaro-Gracia J.M., and Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 144 (1990) 3347-3353
20. Gregersen P.K. Pathways to gene identification in rheumatoid arthritis: PTPN22 and beyond. Immunol. Rev. 204 (2005) 74-86
21. Gregersen P.K., Silver J., and Winchester R.J. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30 (1987) 1205-1213
22. Hurd E.R. Extraarticular manifestations of rheumatoid arthritis. Semin. Arthritis Rheum. 8 3 (1979) 151-176
23. Husby G. Amyloidosis. Semin. Arthritis Rheum. 22 2 (1992) 67-82
24. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., and Braun M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N. Engl. J. Med. 345 15 (2001) 1098-1104
25. Kiener H.P., Baghestanian M., and Dominkus M. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum. 41 2 (1998) 233-245
26. Kiener H.P., Niederreiter B., Lee D.M., Jimenez-Boj E., Smolen J.S., and Brenner M.B. Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. Arthritis Rheum. 60 5 (2009) 1305-1310
27. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., Mola E.M., Pavelka K., Sany J., Settas L., Wajdula J., Pedersen R., Fatenejad S., and Sanda M. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
28. Landewe R., van der Heijde D., Klareskog L., van V.R., and Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum. 54 10 (2006) 3119-3125
29. Liang K.P., Liang K.V., Matteson E.L., McClelland R.L., Christianson T.J., and Turesson C. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum. 54 2 (2006) 642-648
30. Lipsky P.E., Van der Heijde D.M.F.M., St. Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldman M., Harriman G.R., and Maini R.N. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 22 (2000) 1594-1602
31. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., Antoni C., Leeb B., Elliott M.J., Woody J.N., Schaible T.F., and Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41 9 (1998) 1552-1563
32. Mitchison N.A. Induction of immunological paralysis in two zones of dosage. Proc. R. Soc. Lond. B Biol. Sci. 161 (1964) 275-292
33. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., Richert J.R., and Siegel J.N. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 44 12 (2001) 2862-2869
34. Muller-Ladner U., Kriegsmann J., Franklin B.N., et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am. J. Pathol. 149 5 (1996) 1607-1615
35. Partsch G., Steiner G., Leeb B.F., Dunky A., Broll H., and Smolen J.S. Highly elevated levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol. 24 (1997) 518-523
36. Pincus T., and Callahan L.F. What is the natural history of rheumatoid arthritis? Rheum Dis. Clin. North Am. 19 (1993) 123-151
37. Pincus T., and Wolfe F. "No evidence of disease" in rheumatoid arthritis using methrotrexate in combination with other drugs: a contemporary goal for rheumatology care?. Clin. Exp. Rheumatol. 15 (1997) 591-596
38. Pincus T., Yazici Y., Yazici H., Kavanaugh A.F., Kremer J.M., and Wolfe F. Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al. Arthritis Rheum. 52 12 (2005) 4044-4045
39. Remmers E.F., Plenge R.M., Lee A.T., Graham R.R., Hom G., Behrens T.W., de Bakker P.I.W., Hye-Soon Lee J.M.L., Batliwalla F., Li W., Masters S.L., Booty M.G., Carulli J.P., Padyukov L., Alfredssom L., Klareskog L., Chen W.V., Amos C.I., Criswell L.A., Seldin M.F., Kastner D.L., and Gregersen P.K. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357 10 (2007) 977-986
40. Smolen J.S., and Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann. Rheum. Dis. 63 (2004) 221-225
41. Smolen J.S., Kalden J.R., and Scott D.L. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 353 (1999) 259-266
42. Smolen J.S., Han C., Bala M., Maini R.N., Kalden J.R., van der Heijden D.M.F.M., Breedveld F.C., Furst D.E., and Lipsky P.E. Evidence of radiographic benefit of infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of the ATTRACT Trial. Arthritis Rheum. 52 (2005) 1020-2030
43. Smolen J.S., Maini R.N., Han C., Baker D., and Lipsky P.L. Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: reply to comment by Pincus et al. Arthritis Rheum. 52 12 (2005) 4045-4047
44. Smolen J.S., van der Heijde D.M.F.M., St. Clair E.W., Emery P., Bathon J.M., Keystone E., Maini R.N., Kalden J.R., Schiff M., Baker D., Han C., Han J., and Bala M. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab. Results from the ASPIRE trial. Arthritis Rheum 54 (2006) 702-710
45. Smolen J.S., Han C., Van der Heijde D.M.F.M., Emery P., Bathon J.M., Keystone E., Maini R.N., Kalden J.R., Aletaha D., Baker D., Han J., Bala M., and St. Clair E.W. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann. Rheum. Dis. 68 6 (2009) 823-827
46. Smolen J.S., Aletaha D., Grisar J., Redlich K., Steiner G., and Wagner O. The need for prognosticators in rheumatoid arthritis. Biological and clinical markers - where are we now?. Arthritis Res. Ther. 10 3 (2008) 208
47. Smolen, J.S., Aletaha, D., Grisar, J.C., Stamm, T.A., Sharp, J.T., in press. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann. Rheum. Dis. (Electronic publication ahead of print). doi:10.1136/ard.2009.114652.
48. St. Clair E.W., van der Heijde D.M.F.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., Keystone E., Schiff M., Kalden J.R., Wang B., De Woody K., Wiess R., and Baker D. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50 (2004) 3432-3443
49. Steiner G., Tohidast-Akrad M., and Witzmann G. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 38 (1999) 202-213
50. Tak P.P. Analyzing synovial tissue samples. What can we learn about early rheumatoid arthritis, the heterogeneity of the disease, and the effects of treatment?. J. Rheumatol. 32 Suppl 72 (2005) 25-26
51. Tugwell P., Pincus T., and Yocum D. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N. Engl. J. Med. 333 3 (1995) 137-141
52. van den Berg W.B., and van Riel P.L. Uncoupling of inflammation and destruction in rheumatoid arthritis: myth or reality?. Arthritis Rheum. 52 (2005) 995-999
53. van der Heijde D.M.F.M., van Riel P.L., Nuver-Zwart G., and van de Putte L. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1 (1989) 1036-1038
54. van Leeuwen M.A., Van der Heijde D.M.F.M., and van Rijswijk M.H. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J. Rheumatol. 21 3 (1994) 425-429
55. Vastesaeger N., Xu S., Aletaha D., St Clair E.W., and Smolen J.S. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 48 9 (2009) 1114-1121
56. Weinblatt M.E. Efficacy of methotrexate in rheumatoid arthritis. Br. J. Rheumatol. 34 Suppl 2 (1995) 43-48
57. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., Jackson C.G., Lange M., and Burge J.D. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340 4 (1999) 253-259
58. Weyand C.M. New insights into the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 39 Suppl 1 (2000) 3-8
59. Williams R.O., Feldmann M., and Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 9784-9788
60. Wolfe F. The natural history of rheumatoid arthritis. J. Rheumatol. 44 (1996) 13-22 Suppl
61. Wolfe F.E., and Hawley D.J. The longterm outcome of rheumatoid arthritis. Work disability: a prospective 18 year study of 816 patients. J. Rheumatol. 25 (1998) 2108-2117
62. Zvaifler N.J. New perspectives on the pathogenesis of rheumatoid arthritis. Am. J. Med. 85 4A (1988) 12-17